中信证券股份有限公司 关于恩威医药股份有限公司 2024年度持续督导培训情况的报告 深圳证券交易所： 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）根据《深圳证 券交易所上市公司自律监管指引第 13 号——保荐业务》（以下简称"自律监管指 引"）对恩威医药股份有限公司（以下简称"恩威医药"、"公司"）进行了 2024 年度持续督导培训，报告如下： 导培训。 保荐人认为：通过本次培训，公司董事、监事、高级管理人员及控股股东相 关人员对相关法律法规、信息披露要求有了更全面的了解。本次持续督导培训总 体上提高了公司及其董事、监事、高级管理人员和相关人员的规范运作意识，有 助于提高公司的规范运作和信息披露水平。 2 一、本次持续督导培训的基本情况 （七）培训内容：本次培训结合相关法律法规和监管指引，重点介绍了募集 资金使用及上市公司信息披露等规范运作要求，说明了应当及时通知或者咨询保 荐人的事项，加深了公司董事、监事、高级管理人员及控股股东相关人员对相关 法律法规、信息披露要求的理解。 二、上市公司的配合情况 保荐人本次持续督导培训的工作过程中，公司积极予以配合，保证了培训工 作的有序进行，达到了良好效果。 ...

中信证券股份有限公司 关于恩威医药股份有限公司 2024 年度持续督导定期现场检查报告 金使用进度，取得上市公司出具的 2024 年度募集资金存放与使用情况的专项报 告和会计师出具的募集资金存放与实际使用情况鉴证报告，访谈公司董事、高级 管理人员。 | 1.是否在募集资金到位后一个月内签订三方监管协议 | √ | | --- | --- | | 2.募集资金三方监管协议是否有效执行 | √ | | 3.募集资金是否不存在第三方占用或违规进行委托理财等 | √ | | 情形 | | | 4.是否不存在未履行审议程序擅自变更募集资金用途、暂 | √ | | 时补充流动资金、置换预先投入、改变实施地点等情形 | | | 5.使用闲置募集资金暂时补充流动资金、将募集资金投向 | | | 变更为永久性补充流动资金或者使用超募资金补充流动资 | √ | | 金或者偿还银行贷款的，公司是否未在承诺期间进行风险 | | | 投资 | | | 6.募集资金使用与已披露情况是否一致，项目进度、投资 | √ | | 效益是否与招股说明书等相符 | | | 7.募集资金项目实施过程中是否不存在重大风险 | √ | | | --- | ...

登录新浪财经APP 搜索【信披】查看更多考评等级 恩威医药股份有限公司 关于控股股东一致行动人增持股份触及1%暨增持计划进展情况的公告 证券代码：301331 证券简称：恩威医药 公告编号：2025-022 恩威医药股份有限公司 关于控股股东一致行动人增持股份触及1% 暨增持计划进展情况的公告 公司控股股东一致行动人成都杰威企业管理有限公司保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 恩威医药股份有限公司（以下简称"公司"）于2025年1月21日披露了《关于控股股东一致行动人取得金 融机构增持贷款承诺暨增持公司股份计划的公告》（公告编号：2025-002），公司控股股东一致行动人 成都杰威企业管理有限公司（以下简称"成都杰威"）基于对公司未来持续稳定发展的信心和长期投资价 值的认可，为增强投资者信心，成都杰威计划自增持计划公告之日起6个月内，通过集中竞价的方式增 持公司A股股份。总体增持金额不低于人民币3,600万元，不超过人民币7,200万元。 公司于2025年5月8日收到成都杰威《关于增持股份比例触及 ...

| 1.基本情况 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 信息披露义务人 | | 成都杰威企业管理有限公司 | | | | | | 住所 | | 成都高新区创业路 28 号 1 栋 | | | | | | 权益变动时间 | | 年 月 2025 | 5 | 7 | 日 | | | 股票简称 | 恩威医药 | 股票代码 | | | | 301331 | 1 证券代码：301331 证券简称：恩威医药 公告编号：2025-022 恩威医药股份有限公司 关于控股股东一致行动人增持股份触及 1%暨增持计划进展 情况的公告 公司控股股东一致行动人成都杰威企业管理有限公司保证向本 公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 恩威医药股份有限公司（以下简称"公司"）于 2025 年 1 月 21 日披露了《关 于控股股东一致行动人取得金融机构增持贷款承诺暨增持公司股份计划的公告》 （公告编号：2025-002），公司控股股东一致行动人成都杰威企 ...

Group 1: Financial Performance - In 2024, the company achieved operating revenue of 812.13 million yuan, a year-on-year increase of 3.43% [7] - The net profit attributable to shareholders was 37.50 million yuan, showing a decline compared to the previous year due to non-operating factors [7] - The company aims for a revenue target of 1 billion yuan and plans to double its net profit in 2025 [5] Group 2: Sales and Profit Margins - The gross margin for online sales is approximately 60%, while offline sales have a gross margin of around 50% [2] - The company is focusing on expanding its online sales, which require higher promotional expenses [2] Group 3: Strategic Initiatives - External mergers and acquisitions are a key strategy for future growth, with the company actively monitoring potential targets [3] - The company has successfully restructured Henan Xinxin Pharmaceutical, adding 125 products to its portfolio, including 4 exclusive items [3] - Plans to launch 30 new non-pharmaceutical personal care products in 2025, targeting various consumer segments [6] Group 4: Product Development and Market Expansion - The company is prioritizing the launch of key products from Henan Xinxin Pharmaceutical, with the first batch including antiviral oral liquids and heat-clearing detoxification oral liquids [5] - The company aims to cultivate 8 to 10 products with annual sales exceeding 100 million yuan, ensuring long-term sustainable growth [6] - Continuous collaboration with hospitals and research institutions to enhance the value of core products like Jier Yin Wash [3][7]

Core Viewpoint - The controlled nuclear fusion sector is experiencing significant growth, driven by recent advancements and investments in fusion technology, particularly highlighted by the completion of the world's largest superconducting magnet system by the ITER organization [3]. Group 1: Market Performance - On May 6, the controlled nuclear fusion sector saw strong performance, with stocks such as Jiusheng Electric rising by 20%, and companies like Hailu Heavy Industry, Xue Ren Co., and others also experiencing significant gains [1]. - Notable stock performances included: - Heguang Intelligent: +10.00% with a market cap of 5.33 billion - Jiusheng Electric: +19.97% with a market cap of 3.46 billion - Other companies also reported gains exceeding 10% [2]. Group 2: Industry Developments - The ITER project, a major international collaboration involving multiple countries, aims to explore the commercial viability of controlled nuclear fusion technology, marking a significant milestone in the field [3]. - There is a growing trend of collaboration between leading IT and transportation companies with nuclear energy firms to develop small reactors for powering data centers and other applications [3]. Group 3: Institutional Insights - The nuclear fusion sector is recognized as a burgeoning industry, with increasing government support and capital investment, attracting long-term investments from major companies like Amazon and Microsoft [4]. - The Tokamak nuclear fusion market is projected to reach 681 billion by 2025-2030, with potential growth to 3 trillion by 2030-2035 as commercial reactors become operational [4]. - In China, nuclear power equipment investment is expected to grow from 25.7 billion in 2023 to a peak of 87.5 billion by 2028, indicating a compound annual growth rate (CAGR) of 26.91% [4].

Group 1 - Enwei Pharmaceutical reported a revenue of 196 million yuan in Q1 2025, a year-on-year increase of 7.1%, and a net profit attributable to shareholders of 14.62 million yuan, up 118.93% year-on-year [1] - The growth in Q1 2025 is attributed to the acquisition of Henan Xinxin Pharmaceutical, with the first batch of key products launched at the end of 2024 contributing to market growth [1] - The company plans to launch over 20 products in four batches from Q2 to Q3 2025, including significant products like Jian'er Pills and Wujihuai Feng Pills, which are expected to enhance revenue and profit [1] Group 2 - Enwei Pharmaceutical has operated the "Jie'er Yin" brand for 39 years, developing a comprehensive product matrix that includes various forms of Jie'er Yin products [2] - The Jie'er Yin series has sold over 700 million bottles, with the core product, Jie'er Yin Wash, consistently ranking first in the market share of gynecological traditional Chinese medicine in urban retail pharmacies [2] - The company plans to distribute a cash dividend of 1.8 yuan per 10 shares, totaling approximately 18.19 million yuan, to enhance shareholder returns [2] Group 3 - The company aims to improve product quality and user experience through process and packaging enhancements while focusing on the market strategy for Henan Xinxin Pharmaceutical's product launches [3] - Enwei Pharmaceutical has established advantages in the gynecological product sector, with a growing market size driven by increased health awareness among women [3] - The company is also expanding its market efforts in pediatric and respiratory medications, aiming for sustainable growth in the healthcare market through diversified business strategies and continuous innovation [3]

证券代码：301331 证券简称：恩威医药 公告编号：2025-021 恩威医药股份有限公司 关于一致行动人股份增持计划期限过半的进展公告 公司控股股东一致行动人成都杰威企业管理有限公司保证向本 公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。本公司及董事会全体成员保证公告内容与信息披露义务 人提供的信息一致。 特别提示： 1、恩威医药股份有限公司（以下简称"公司"）控股股东成都恩威投资（集 团）有限公司（以下简称"恩威集团"）一致行动人成都杰威企业管理有限公司 （以下简称"成都杰威/增持主体"）于 2025 年 1 月 21 日披露了《关于一致行动 人取得金融机构增持贷款承诺暨增持公司股份计划的公告》（公告编号： 2025-002），基于对公司未来持续稳定发展的信心和长期投资价值的认可，为增 强投资者信心，成都杰威计划自本公告之日起 6 个月内，通过集中竞价的方式增 持公司 A 股股份。总体增持金额不低于人民币 3,600 万元，不超过人民币 7,200 万元。 2、截至本公告披露日，本次增持计划实施期限已过半。2025 年 1 月 21 日 至 2025 年 4 月 20 日期间 ...

Fundraising Overview - The company raised a total of RMB 522.69 million through the issuance of 17,540,000 shares at a price of RMB 29.80 per share, with a net amount of RMB 442.95 million after deducting issuance costs [2][3] - Prior to the funds being in place, the company had already invested RMB 156.71 million from self-raised funds into projects and paid RMB 20.53 million in issuance costs [3] - As of December 31, 2023, the company had accumulated interest income and cash management product returns of RMB 5.48 million, with a total of RMB 169.18 million remaining in the fundraising account [4] Fund Utilization - In the reporting period, the company invested RMB 47.08 million in fundraising projects and permanently supplemented working capital with RMB 11.37 million [5] - By December 31, 2024, the total direct investment in fundraising projects reached RMB 66.09 million, with RMB 156.71 million used to replace self-raised funds [5][6] - The company has established a management system for fundraising, ensuring funds are stored in dedicated accounts and used according to strict approval procedures [6][28] Internal Control Evaluation - The company conducted an internal control evaluation as of December 31, 2024, concluding that there were no significant defects in financial reporting controls [13][41] - The internal control framework includes governance structures, risk assessment, and control activities across various operational areas, ensuring compliance with relevant laws and regulations [14][24][28] - The company has established a robust internal audit function to monitor compliance and effectiveness of internal controls [36] Profit Distribution Proposal - The board of directors approved a profit distribution proposal for 2024, recommending a cash dividend of RMB 1.80 per share, totaling approximately RMB 18.19 million [53][55] - The proposal is in line with the company's profit distribution policy and aims to provide reasonable returns to shareholders while ensuring the company's sustainable development [55][57] - The company has maintained a strong cash dividend history, exceeding the average net profit over the past three years [56]

数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.1635 | 0.0828 | 97.46 | 0.3945 | | 每股净资产（元） | 0 | 15.39 | -100 | 16.83 | | 每股公积金(元) | 6.23 | 9.69 | -35.71 | 9.48 | | 每股未分配利润(元) | 3.45 | 5.21 | -33.78 | 5.86 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 1.96 | 1.83 | 7.1 | 2.01 | | 净利润(亿元) | 0.16 | 0.08 | 100 | 0.28 | | 净资产收益率(%) | | 0.77 | -100 | 2.37 | 本次公司不分配不转赠。 前十大流通股东累计持有： 571.2万股，累计占流通股比： 17.27%，较 ...